Avidity Partners Management’s AstraZeneca AZN Stock Holding History

Avidity Partners Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-102,500	Closed	-$16M	–	84
2024 Q2	$16M	Buy	102,500 +22,500	+28%	+$3.39M	0.68%	52
2024 Q1	$10.8M	Buy	+80,000	New	+$10.6M	0.35%	72
2023 Q1	–	Sell	-600,000	Closed	-$81.4M	–	84
2022 Q4	$81.4M	Buy	600,000 +318,400	+113%	+$39.9M	1.76%	19
2022 Q3	$30.9M	Sell	281,600 -1,467,900	-84%	-$186M	0.63%	48
2022 Q2	$231M	Sell	1,749,500 -100,500	-5%	-$13.2M	5.31%	1
2022 Q1	$245M	Buy	1,850,000 +416,400	+29%	+$49.9M	5.11%	2
2021 Q4	$167M	Buy	1,433,600 +727,600	+103%	+$85.6M	3.54%	5
2021 Q3	$84.8M	Buy	+706,000	New	+$82.2M	1.88%	15
2021 Q2	–	Sell	-1,825,250	Closed	-$182M	–	119
2021 Q1	$182M	Buy	1,825,250 +675,250	+59%	+$67.9M	5.01%	2
2020 Q4	$115M	Buy	+1,150,000	New	+$122M	3.73%	5
2020 Q3	–	Sell	-162,995	Closed	-$17.2M	–	72
2020 Q2	$17.2M	Buy	+162,995	New	+$16.8M	1.11%	37

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Avidity Partners Management's AZN Position: Q3 2024 in Review

Avidity Partners Management sold out of AstraZeneca (AZN) in Q3 2024, closing a stake of 102,500 shares — an estimated $16M sold.

Avidity Partners Management first reported a position in AZN in Q2 2020 and held it in 11 quarters. The position peaked at $245M in Q1 2022. 1,229 funds tracked by Wall St. Rank hold AZN as of Q3 2024.

Avidity Partners Management reported no remaining AstraZeneca position as of Q3 2024 after selling out during the quarter.
Avidity Partners Management sold 102,500 AstraZeneca shares in Q3 2024, an estimated $16M.
Avidity Partners Management first reported a position in AstraZeneca in Q2 2020 and held it in 11 quarters.
Avidity Partners Management's AstraZeneca position peaked at $245M in Q1 2022.
1,229 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.

Based on Avidity Partners Management's 13F filing for Q3 2024, filed 14 Nov 2024.